HER2+ Breast Cancer
Conditions
Brief summary
This study evaluated the clinical benefits of intravenous administration of pyrotinib combined with trastuzumab subcutaneous preparation by comparing the efficacy and quality of life of intravenous administration in the treatment of HER2-positive early breast cancer
Interventions
DRUGTrastuzumab intravenous drip/Trastuzumab Subcutaneous Injection
Group A is Trastuzumab intravenous drip,Group B is Trastuzumab Subcutaneous Injection
Sponsors
Jiangsu Famous Medical Technology Co., Ltd.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Inclusion criteria
1. Women aged ≥18 years and ≤75 years who are newly treated for breast cancer; 2. Pathological examination confirmed HER2 positive (immunohistochemical staining ICH+++ or ICH++ and FISH positive); 3. Patients with invasive breast cancer diagnosed histologically plus imaging as early (T1c-3, N0-1, M0) or locally advanced (T2-3, N2, or N3, M0); 4. ECOG score 0-1; 5. Plan to undergo the final surgical removal of breast cancer, i.e. breast-conserving surgery or total mastectomy, sentinel lymph node (SN) biopsy or axillary lymph node dissection (ALND); 6. If the major organs function normally, the following criteria are met: (1) The standard of blood routine examination should meet: ANC ≥1.5×109/L; PLT ≥90×109/L; Hb ≥90g/L; (2) Biochemical examination should meet the following criteria: TBIL≤ upper limit of normal value (ULN); ALT and AST≤1.5 times the upper limit of normal (ULN); Alkaline phosphatase ≤2.5 times the upper limit of normal (ULN); BUN and Cr≤1.5×ULN and creatinine clearance ≥50 mL/min (Cockcroft-Gault formula); (3) Color Doppler ultrasonography and echocardiography: left ventricular ejection fraction (LVEF≥55%); (4) Fridericia calibrated QT interval (QTcF) for 18-lead ECG \<470 ms; 7. For female patients who are not menopausal or have not been surgically sterilized, they should consent to abstinence or use an effective contraceptive method during treatment and for at least 7 months after the last dose in the study treatment. 8\. Volunteer to join the study and sign the informed consent.
Exclusion criteria
1. Known allergic history of the drug components of this protocol; 2. Previously received antitumor therapy or radiation therapy for any malignant tumor (except for cured cervical carcinoma in situ and basal cell carcinoma); 3. Has undergone major non-breast cancer related surgery within 4 weeks, or has not fully recovered from such surgery; 4. Stage IV (metastatic) breast cancer patients; 5. Inability to swallow, intestinal obstruction, or other factors affecting the administration and absorption of the drug; 6. Serious heart disease or discomfort that cannot be treated; 7. Suffering from mental illness or psychotropic substance abuse, unable to cooperate; 8. Pregnant or lactating women; 9. Patients with severe liver and kidney function diseases and blood system diseases; 10. Those who were not considered suitable for inclusion by the researchers included: history of drug abuse, history of use of blood products, anticoagulant drugs and immunological drugs within the past year; Poor compliance and refusal to cooperate with treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| EORTC QLQ-C30 scale score | through study completion, an average of 1 year | PRO scale scores between two groups collected at different time points |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| tpCR | 1-2 weeks after surgery | total pathological complete response |
Outcome results
None listed